Deucravacitinib Improves Cutaneous Lupus Erythematosus Activity

Victoria Werth, MD, a professor of Dermatology, investigated repurposing a currently FDA-approved medication to treat cutaneous lupus erythematosus (CLE), an autoimmune disease. The study, a phase 2 trial of the drug deucravacitinib already in use and approved to reduce symptoms of plaque psoriasis, found that deucravacitinib helped relieve symptoms and minimize damage caused by CLE.